Novel LIFR Variant Identified in Stuve-Wiedemann Syndrome
Case report highlights the role of early genetic confirmation in severe skeletal dysplasia
By
Henry Thomas
February 10, 2026
Clinical Scorecard: Novel LIFR Variant Identified in Stuve-Wiedemann Syndrome
At a Glance
Category Detail
Condition Stüve-Wiedemann syndrome Key Mechanisms Disruption of LIFR-mediated signaling affecting skeletal development and autonomic function. Target Population Infants diagnosed with Stüve-Wiedemann syndrome. Care Setting Pediatric care, genetic testing facilities.
Key Highlights
Characterized by bowed long bones, joint contractures, and severe dysautonomia. Associated with homozygous or compound heterozygous LIFR variants. High early-life morbidity and mortality, with a global mortality rate of 46%. Longer-term survival reported in some patients beyond the first two years. Molecular confirmation aids in distinguishing from other skeletal dysplasias. Guideline-Based Recommendations
Diagnosis
Genetic testing for LIFR variants to confirm diagnosis. Management
Supportive care for dysautonomia and associated complications. Monitoring & Follow-up
Regular assessment of growth parameters and respiratory function. Risks
High risk of early mortality, particularly within the first two years. Patient & Prescribing Data
Infants with confirmed Stüve-Wiedemann syndrome.
Focus on managing symptoms and complications associated with dysautonomia.
Clinical Best Practices
Early genetic testing for suspected cases. Multidisciplinary approach to manage complex symptoms. Education for caregivers regarding potential complications. References
